Vanda Pharmaceuticals, Inc. (VNDA) Misses Q1 Views

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q1 EPS of ($0.28), $0.12 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $8.14 million versus the consensus estimate of $8.3 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c